Pharmaceutical composition for combination therapy containing dual inhibitor of c-Met and EGFR and IGF-1R inhibitor

c-Met and EGFR dual inhibitors, and for preventing and / or pharmaceutical composition for co-administration for the treatment, anti-c-Met and EGFR dual inhibitors efficacy enhancement (resistance of the IGF-1R inhibitors of cancer comprising as an active ingredient, IGF-1R inhibitors is overcome) it uses, and the use of IGF-1R as a resistance marker for c-Met and EGFR dual inhibitors is provided.